Emergent wraps up purchase of Chimerix's potential monkeypox treatment Tembexa

With the monkeypox virus evolving—just as the coronavirus before it—adding new products to combat its spread is a key priority for the U.S.

Monday, Emergent BioSolutions took a step toward being able to address the need, completing its acquisition of smallpox oral antiviral Tembexa.